Literature DB >> 8015334

Multiple myeloma: how did it begin?

R A Kyle1.   

Abstract

OBJECTIVE: To present a historical overview of multiple myeloma.
DESIGN: The pertinent literature, from the early cases of this disorder to subsequent diagnostic advances, was reviewed.
RESULTS: The first well-known case of multiple myeloma (described in the 1840s) was that of Mr. McBean, a highly respectable tradesman from London. Although the features of Bence Jones proteinuria were recognized by his physician, Dr. William Macintyre, urine specimens from Mr. McBean were studied in detail by Henry Bence Jones, a well-known chemical pathologist, who confirmed the findings of Macintyre. The disease was rarely recognized until 1889, when the famous case report by Kahler was published. Interestingly, the subject of this case report (Dr. Loos) survived for 8 years despite inadequate chemotherapy. The role of plasma cells was recognized at the turn of the century. In 1922, Bayne-Jones and Wilson identified two distinct groups of Bence Jones protein, but a relationship between Bence Jones protein and the serum proteins of multiple myeloma was not demonstrated until 1956, in a study performed by Korngold and Lipari. (The designation of the two main classes of Bence Jones protein as kappa and lambda is a tribute to these two investigators.) The major breakthrough was the discovery that light chains from a serum IgG myeloma protein and the Bence Jones protein from the same patient's urine were identical.
CONCLUSION: Multiple myeloma is a devastating disorder of plasma cell proliferation in the bone marrow that can result in skeletal destruction. Immunoelectrophoresis is useful as the initial diagnostic procedure.

Entities:  

Mesh:

Year:  1994        PMID: 8015334     DOI: 10.1016/s0025-6196(12)61349-4

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

Review 1.  Targeted proteomic strategy for clinical biomarker discovery.

Authors:  Ralph Schiess; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Oncol       Date:  2008-12-11       Impact factor: 6.603

Review 2.  More Than Meets the Eye: The Contributions of John Dalrymple (1803-1852).

Authors:  Joy Mh Wang; Bryan Edwards; Gabrielle G Tardieu; Marios Loukas; Rod J Oskouian; R Shane Tubbs
Journal:  Cureus       Date:  2017-06-19

Review 3.  Making Meaningful Clinical Use of Biomarkers.

Authors:  Matthew J Selleck; Maheswari Senthil; Nathan R Wall
Journal:  Biomark Insights       Date:  2017-06-19

Review 4.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

5.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.